StockNews.AI
PLRX
StockNews.AI
146 days

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX

1. Faruqi & Faruqi investigating claims against Pliant Therapeutics. 2. Pliant paused BEACON-IPF Phase 2b trial due to data review. 3. Stock price dropped 60.59% after trial announcement. 4. Wells Fargo and Citi downgraded Pliant post-announcement.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Pliant's recent 60.59% stock drop indicates severe investor loss confidence; historical precedents, like other biotechs under trial failure, often lead to prolonged downturns.

How important is it?

The investigation and significant stock loss indicate potential legal exposure and diminished market confidence, likely affecting future share price substantially.

Why Short Term?

Investors react quickly to trial news; similar events have historically resulted in rapid stock declines or recoveries depending on subsequent developments.

Related Companies

MRTXRPMTNVCR
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. (“Pliant” or the “Company”) (NASDAQ: PLRX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On February 7, 2025, Pliant issued a press release "announc[ing] that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF)." Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast's path forward. On this news, Pliant's stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025. To learn more about the Pliant Therapeutics investigation, go to www.faruqilaw.com/PLRX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/4c96193e-9e8a-4e5d-878a-3e41b441e24a

Related News